Last reviewed · How we verify
Radiotherapy+PCV chemotherapy
Radiotherapy works by damaging the DNA of cancer cells, while PCV chemotherapy targets rapidly dividing cells with a combination of drugs.
Radiotherapy works by damaging the DNA of cancer cells, while PCV chemotherapy targets rapidly dividing cells with a combination of drugs. Used for Glioblastoma.
At a glance
| Generic name | Radiotherapy+PCV chemotherapy |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Radiotherapy uses high-energy rays to kill cancer cells by damaging their DNA, which prevents them from reproducing. PCV chemotherapy, on the other hand, is a combination of three drugs: procarbazine, lomustine, and vincristine. These drugs work by targeting rapidly dividing cells, which are characteristic of cancer cells, and preventing them from reproducing.
Approved indications
- Glioblastoma
Common side effects
- Nausea
- Vomiting
- Fatigue
- Hair loss
- Anemia
Key clinical trials
- A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (PHASE3)
- A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery (PHASE3)
- gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas (PHASE3)
- Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma (PHASE3)
- Triple Negative Breast Cancer and Celecoxib. Pilot Study (PHASE2)
- Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma (PHASE2, PHASE3)
- Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas (EARLY_PHASE1)
- Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiotherapy+PCV chemotherapy CI brief — competitive landscape report
- Radiotherapy+PCV chemotherapy updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI